23 . March , 2018 - Friday
Check todays hot topics or new products

Find a Drug: Advanced

Please Sign in or Register

All about: Micafungin Sodium

Big Image Pronouncation: (mi-ka-FUN-gin SO-dee-uhm)
Class: Antifungal agent

Trade Names:
- Powder for injection 50 mg

Mechanism of Action


Inhibits synthesis of 1,3-B-D-glucan, an essential component of fungal cell walls, but not present in mammalian cells.



More than 99% protein bound, primarily to albumin and to a lesser extent to α 1 -acid-glycoprotein.


Metabolized by arylsufatase, catechol-O-methyltransferase, and hydroxylation catalyzed by CYP450 isoenzymes.


The t ½ is 14 to 17 hr. Fecal excretion is major route of elimination (71%).

Special Populations

Hepatic Function Impairment

Moderate (Child-Pugh score 7 to 9): AUC and C max were reduced about 22% compared with normal hepatic function. No dosage adjustment needed.

Indications and Usage

Treatment of esophageal candidiasis; prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.


Standard considerations.

Dosage and Administration

Esophageal Candidiasis

IV 150 mg once daily by slow infusion over 1 hr.

Prophylaxis of Candida Infections

IV 50 mg once daily by slow infusion over 1 hr.

General Advice

  • For IV infusion only. Not for oral, intradermal, subcutaneous, IM, IV bolus, or intraarterial administration.
  • Reconstitute powder for injection by adding 5 mL sodium chloride injection 0.9% (without a bacteriostatic agent) or dextrose injection 5% to vial. To minimize excessive foaming, gently dissolve powder by swirling the vial until a clear solution is obtained. Do not vigorously shake vial. Final concentration is approximately micafungin 10 mg/mL.
  • For treatment of esophageal candidiasis, add micafungin 150 mg from 3 of the 50 mg vials reconstituted with 15 mL of diluent to 100 mL of sodium chloride injection 0.9% or dextrose injection 5%.
  • For prophylaxis of Candida infections, add micafungin 50 mg from 1 vial reconstituted with 5 mL of diluent to 100 mL sodium chloride injection 0.9% or dextrose injection 5%.
  • Do not mix or co-infuse with other medications.
  • Visually inspect reconstituted solution before use. Do not use if particulate matter, cloudiness, or discoloration noted.
  • Flush existing IV line with sodium chloride injection 0.9% prior to infusing micafungin.
  • Administer by IV infusion over 1 hr. More rapid infusions may result in more frequent histamine mediated reactions.
  • Reconstituted solution contains no preservative. Discard any unused solution.


Store unopened vials at controlled room temperature (59° to 86°F). Reconstituted micafungin solution may be stored in the original vial at room temperature (77°F) for up to 24 hr. Diluted infusion solution can be stored at room temperature (77°F) for 24 hr. Protect diluted infusion solution from light.

Drug Interactions


Plasma levels may be elevated by micafungin, increasing the pharmacologic and adverse effects.


Sirolimus AUC increased but not C max .

Laboratory Test Interactions

None well documented.

Adverse Reactions


Hypotension (1%); shock (postmarketing).


Headache (3%); pyrexia (2%); delirium, dizziness, dysgeusia, somnolence (1%).


Rash (3%); flushing, pruritus (1%).


Nausea (3%); abdominal pain, diarrhea, vomiting (2%); dyspepsia (1%).


Acute renal failure, renal impairment (postmarketing).


Leukopenia (3%); neutropenia, thrombocytopenia, anemia, lymphopenia, febrile neutropenia (1%); decreased WBC, hemolytic anemia (postmarketing).


Hyperbilirubinemia (3%); liver function test abnormalities (2%); hepatic disorder, hepatocellular damage (postmarketing).

Lab Tests

Increased ALT and AST (3%); increased blood alkaline phosphatase (2%); increased blood creatinine, increased blood lactate dehydrogenase, increased transaminase, increased blood urea (1%).


Infusion site inflammation (2%) injection site pain (1%).


Hypokalemia (2%); hypocalcemia, hypomagnesemia, hypophosphatemia, decreased appetite (1%).


Rigors (2%).


Phlebitis (4%).



Evaluate liver and renal function tests prior to and periodically thereafter during treatment. If abnormal liver function tests noted, monitor liver and/or function more frequently. If worsening hepatic and/or renal function is noted, evaluate risk/benefit of continued therapy with micafungin. Monitor patient for clinical and laboratory evidence of hemolysis or hemolytic anemia during treatment. If evidence of hemolysis or hemolytic anemia develops, monitor more frequently. If worsening is suspected, evaluate risk/benefit of continued therapy with micafungin.


Category C .




Safety and efficacy not established.


Isolated cases of serious hypersensitivity (anaphylaxis and anaphylactoid) reactions have occurred. Monitor patient for signs of allergic reaction. Discontinue therapy and immediately notify health care provider if noted. Be prepared to treat appropriately.



None reported.

Patient Information

  • Advise patient or caregiver that medication will be prepared and administered by health care professionals in a hospital setting.
  • Advise patient to immediately report any discomfort at injection site or vein above the injection site.
  • Instruct patient to report any of the following to health care provider: fever, chills, rash, itching, flushing, nausea, any unusual or unexplained symptoms.

Recent Drug Updates at DrugIndexOnline:

Aricept ODT Aricept ODT
Generic Name: donepezil (oral) (doh NEP e zil) Brand Names: Aricept, Aricept ODT What is donepezil? Donepezil improves the function of nerve cells in the brain. It works by preventing the breakdown of a chemical called acetylcholine (ah see til KO leen). People with dementia usually hav more...

D.A. Chewable D.A. Chewable
Some commonly used brand names are: In the U.S.— AH-chew 1 D.A. Chewable 1 Dallergy 1 Dura-Vent/DA 1 Extendryl 1 Extendryl JR 1 Extendryl SR 1 Mescolor 2 OMNIhist L.A. 1 Stahist 3 Note: In November 2000, the Food and Drug Administration (FDA) issued a public health warning regarding more...

Ergocaff-PB Ergocaff-PB
Some commonly used brand names are: In the U.S.— Belcomp-PB 5 Cafergot 3 D.H.E. 45 1 Ergocaff-PB 5 Ergomar 2 Migergot 3 Migracet-PB 5 Wigraine 3 In Canada— Cafergot 3 D.H.E. 1 Ergodryl 8 Gravergol 7 Note: For quick reference, the following ergot derivative-containing headach more...

Estratest H.S. Estratest H.S.
Generic Name: esterified estrogens and methyltestosterone (ess TARE uh fied ESS troe jenz and meth ill tess TOSS ter own) Brand Names: Estratest, Estratest H.S., Menogen, Menogen HS What is Estratest H.S. (esterified estrogens and methyltestosterone)? Esterified estrogens are female sex more...

Fosphenytoin Fosphenytoin
Generic Name: Fosphenytoin sodium Dosage Form: Injection Fosphenytoin Description Fosphenytoin Sodium Injection, USP is a prodrug intended for parenteral administration; its active metabolite is more...

Lodrane 12D Sustained-Release Tablets Lodrane 12D Sustained-Release Tablets
Generic Name: Brompheniramine/Pseudoephedrine Sustained-Release Tablets (brome-fen-EER-ah-meen/soo-doe-eh-FED-rin) Brand Name: Examples include Bidhist-D and Lodrane 12DLodrane 12D Sustained-Release Tablets is used for:Relieving symptoms of sinus congestion, pressure, runny nose, and sneezing d more...

Neomycin,Polymyxin B,Dexamethasone Neomycin,Polymyxin B,Dexamethasone
Generic Name: neomycin sulfate, polymyxin B sulfate, and dexamethasone Dosage Form: Ophthalmic ointment Neomycin,Polymyxin B,Dexamethasone Description Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Ointment USP is a multiple dose anti-infective steroid combination in a sterile oin more...

Probenecid Probenecid
Generic Name: Probenecid (proe-BEN-a-sid) Brand Name: Generic only. No brands available.Probenecid is used for:Treating high levels of uric acid in the blood caused by gout or gouty arthritis. It may be used to increase blood levels of certain antibiotics (eg, penicillin). It may also be used f more...